Lixumistat before and after surgery for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests a new drug called lixumistat as an early treatment for newly diagnosed glioblastoma, given shortly before and after surgery. The goal is to see if the drug can help fight the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a new diagnosis of glioblastoma (a type of brain tumor) and be planning to have surgery to remove it.
- You should be able to care for yourself and manage daily activities (with minimal help if needed).
- You must not have had any prior treatment for this brain tumor.
- You must be able to have an MRI (magnetic resonance imaging) scan with contrast.
- You must be in generally good health with adequate kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This trial tests a new drug called GLIX1 to find a safe dose for people whose high-grade glioma (a fast-growing brain tumor) has come back or is getting worse after earlier treatments. It may be an option if you've had no more than two prior treatments.
This trial tests whether an investigational drug called troriluzole can help people with recurrent glioblastoma (a type of brain tumor). You would take the drug for a short time before your planned surgery, so researchers can study how the drug affects your tumor tissue. The goal is to see if it might slow tumor growth.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial studies a two-step treatment for newly diagnosed high-grade glioma: first laser treatment (LITT) to target the tumor, followed by a shorter, more focused course of radiation. It may help shrink or control the tumor while limiting treatment time.
This trial tests a new targeted drug, TLX101-Tx, added to standard care for people with glioblastoma that has come back after initial treatment. It aims to see if the combination helps control the tumor better than standard care alone.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.